IDEAYA Biosciences, Inc. Receivables, Net, Current
IDEAYA Biosciences, Inc. (IDYA) had Receivables, Net, Current of $3.00 thousand as of 2024-12-31, per its 10-K filed 2025-02-18.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2025-02-18
- 2024-12-31: Receivables, Net, Current $3.00K.
- 2024-09-30: Receivables, Net, Current $20.00K.
- 2024-06-30: Receivables, Net, Current $1.00K.
- 2024-03-31: Receivables, Net, Current $15.00K.
| Period end | Receivables, Net, Current |
|---|---|
| 2024-12-31 | $3.00K 10-K · filed 2025-02-18 |
| 2024-09-30 | $20.00K 10-Q · filed 2024-11-04 |
| 2024-06-30 | $1.00K 10-Q · filed 2024-08-06 |
| 2024-03-31 | $15.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $18.00K 10-K · filed 2025-02-18 |
| 2023-09-30 | $6.70M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $160.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $468.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $211.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | $3.45M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $288.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $697.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $1.10M 10-K · filed 2023-03-07 |
| 2021-09-30 | $1.02M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.32M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $2.92M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $1.88M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |